Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for cancer and infectious diseases, raised $84 million by offering 6 million shares at $14, the low end of the range of $14 to $16. It had previously filed to offer 6.7 million shares at the same range. Hookipa Pharma plans to list on the Nasdaq under the symbol HOOK. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as lead managers on the deal.
The article Immuno-oncology biotech Hookipa Pharma prices downsized IPO at $14 low end originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
